Table 1 National and retail audit of oral anti-malarial drugs available on the Kenyan market in 2002
From: Brands, costs and registration status of antimalarial drugs in the Kenyan retail sector
| Â | National audit | Retail audit | |||
|---|---|---|---|---|---|
Generic Name | # Brands identified (registered)* | Median (IQR) cost (USD) of treatment course †| # Brands identified (registered)* | # Outlets stocking (%) | Median (IQR) cost (USD) of treatment course †|
SP tablets | 49 (29) | 0.19 [0.13, 0.32] | 30 (16) | 250 (28.5%) | 0.38 [0.25, 0.65] |
SP suspensions and drops‡ | 16 (5) | 0.39 [0.28, 0.53] | 15 (2) | 57 (6.5%) | 0.44 [0.44, 0.56] |
AQ tablets | 22 (12) | 0.17 [0.14, 0.55] | 13 (6) | 818 (93.4%) | 0.76 [0.76, 0.76] |
AQ suspensions | 11 (5) | 0.28 [0.15, 0.49] | 12 (5) | 71 (8.1%) | 0.51 [0.39, 0.60] |
CQ tablets | 43 (33) | 0.09 [0.08, 0.19] | 12 (5) | 132 (15.1%) | 0.44 [0.25, 0.44] |
CQ syrups | 22 (10) | 0.05 [0.03, 0.30] | 9 (4) | 12 (1.4%) | 0.26 [0.06, 0.31] |
QN tablets | 25 (19) | 2.73 [2.40, 3.16] | 3 (2) | 32 (3.7%) | 3.20 [2.40, 4.00] |
QN drops and mixtures | 3 (1) | 2.24 [1.87, 3.00] | 4 (1) | 49 (5.6%) | 4.00 [3.27, 4.00] |
ART tabs | 11 (11) | 5.34 [4.16, 5.56] | 7 (7) | 24 (2.7%) | 7.11 [6.14, 7.96] |
ART suspensions | 1 (0) | 3.86 [3.86, 3.86] | 2 (0) | 21 (2.4%) | 5.00 [4.44, 5.13] |
MEF tablets | 4 (4) | 5.04 [3.83, 9.53] | 4 (4) | 14 (1.6%) | 7.61 [7.33, 7.87] |
HAL tablets | 1 (1) | 7.96 [7.96, 7.96] | 1 (1) | 22 (2.5%) | 9.90 [9.26, 10.25] |
HAL suspensions | 1 (1) | 2.83 [2.83, 2.83] | 1 (1) | 18 (2.1%) | 3.55 [3.20, 3.71] |
Other tablets | 9 (6) | 3.62 [0.35, 13.20] | 1 (1) | 18 (2.1%) | 17.51 [17.51, 17.51] |